Allergen inhalation challenge, refractoriness and the effects of ibuprofen

Abstract

BackgroundBronchoprovocation challenges use direct or indirect acting stimuli to induce airflow obstruction. Indirect stimuli either non-allergic/non-IgE mediated (e.g. exercise, mannitol) or allergic/IgE mediated (i.e. allergen) trigger mast cells to release bronchoconstricting mediators (e.g. cysteinyl leukotrienes, histamine). Performing repeat challenges within a short timeframe (e.g. 3 h) with non-allergic indirect stimuli results in a diminished, refractory response to the second challenge that is inhibited by non-steroidal anti-inflammatory medications. Cross refractoriness occurs between indirect stimuli. It follows that repeat bronchoprovocation with allergen might exhibit refractoriness that might be altered by ibuprofen. We assessed the response to a second allergen challenge performed 24 h after an initial allergen challenge to determine if the response is refractory. If refractoriness developed, the study aimed to determine whether a single dose of ibuprofen would alter the refractory response to the second allergen challenge. In the absence of a refractory response, the study design allowed for the assessment of the effect of ibuprofen on allergen challenge outcomes, including indices of airway inflammation.MethodsThirteen mild atopic asthmatics were enrolled in a randomized, double-blind, placebo controlled, cross-over study. Ibuprofen (400 mg) or placebo was administered 1 h prior to the first of two allergen challenges, performed 24 h apart. Blood and sputum eosinophils, airway responsiveness to methacholine and levels of fractional exhaled nitric oxide were assessed before and 7 h after each allergen challenge. All data were log transformed and differences in geometric means were analyzed by paired t-tests.ResultsAfter placebo, early asthmatic responses for the two challenges were not significantly different (p = 0.82). A single 400 mg dose of ibuprofen decreased both the early (p = 0.03; n = 12) and late asthmatic responses (p = 0.03; n = 3).ConclusionAllergen challenges conducted 24 h apart do not exhibit refractoriness. Single dose ibuprofen inhibits early and late asthmatic responses to allergen bronchoprovocation. Ibuprofen should be withheld for at least 24 h prior to investigations utilizing allergen bronchoprovocation.Trial registration clinicaltrials.gov #NCT02327234

Working Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal

“…Another large review of the literature (472 articles) demonstrated that not only is there a low risk of ibuprofen-induced asthma in children, but that the drug might have protective and therapeutic effects [ 61 ]. Interestingly, it was recently suggested that ibuprofen reduces the late response to specific bronchoprovocation with allergens and could, therefore, have a protective effect in allergen-induced asthma [ 62 ], but further evidence is required.…”

Drug-Induced Pseudoallergy: A Review of the Causes and Mechanisms

“…Different from IgE-mediated allergy, which is mediated by cell-surface receptors, the drugs are able to induce mast cell degranulation and alter enzymatic activity through various pathways [34,35]. Cysteinyl LTs (cysLTs) and histamine, released by mast cells, mediate bronchoconstriction [36]. …”

Allergen Challenge Testing in Atopic Asthma Pharmaceutical Research: Past, Present, and Future Directions

“…If we include early responders, we may be able to gain insight into allergen-induced increases in AHR since early responders show an increase at 3 hours post allergen challenge. 40 At 24 hours post challenge, early responders have also shown increased AHR, 41 as well as increased eosinophils and fractional exhaled nitric oxide, 42 but without developing a classic LAR. By using a method that incorporates both the classic dual and EAR models (i.e.…”

“…31 Some studies have shown that the inclusion of participants who fell between 10-15% during the LAR time frame strengthened the data set, especially considering that these participants showed similar results to those who had met the current LAR criteria. 31,42 Future allergen challenge models could potentially reduce the cut-off point for defining the LAR to 10% without negatively influencing study outcomes.…”